Moomoo AIのまとめ
On May 31, 2024, Novo Integrated Sciences, Inc. announced the approval by its Board of Directors of a Stock Repurchase Program, authorizing the repurchase of up to $5 million of the company's common stock. The repurchases may occur in the open market or through privately negotiated transactions, depending on market conditions and other factors. Additionally, the Board is reviewing the possibility of increasing the repurchase amount, contingent upon the availability of excess funds from a program designed to monetize a Standby Letter of Credit, which is part of the Ophir Collection acquisition strategy. The timing and volume of repurchases will be subject to management's discretion, considering factors such as stock price, market conditions, and the company's capital position. The program does not commit Novo Integrated Sciences to a specific number of shares and may be suspended at any time. The announcement was made in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
On May 31, 2024, Novo Integrated Sciences, Inc. announced the approval by its Board of Directors of a Stock Repurchase Program, authorizing the repurchase of up to $5 million of the company's common stock. The repurchases may occur in the open market or through privately negotiated transactions, depending on market conditions and other factors. Additionally, the Board is reviewing the possibility of increasing the repurchase amount, contingent upon the availability of excess funds from a program designed to monetize a Standby Letter of Credit, which is part of the Ophir Collection acquisition strategy. The timing and volume of repurchases will be subject to management's discretion, considering factors such as stock price, market conditions, and the company's capital position. The program does not commit Novo Integrated Sciences to a specific number of shares and may be suspended at any time. The announcement was made in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
2024年5月31日、Novo Integrated Sciences, Inc.は、取締役会の承認により、同社の普通株式の最大5百万ドルまでの自社株買いプログラムを発表しました。買い戻しは、市場状況やその他の要因に応じてオープンマーケットまたは非公開取引によって行われる可能性があります。さらに、取締役会は、Ophir Collectionの取得戦略の一部であるStandby Letter of Creditを現金化するためのプログラムから余剰資金が利用可能になった場合、自社株買い金額を増やす可能性を検討しています。買戻しのタイミングと出来高は、自社株価、市場状況、および同社の資本状況などの要...すべて展開
2024年5月31日、Novo Integrated Sciences, Inc.は、取締役会の承認により、同社の普通株式の最大5百万ドルまでの自社株買いプログラムを発表しました。買い戻しは、市場状況やその他の要因に応じてオープンマーケットまたは非公開取引によって行われる可能性があります。さらに、取締役会は、Ophir Collectionの取得戦略の一部であるStandby Letter of Creditを現金化するためのプログラムから余剰資金が利用可能になった場合、自社株買い金額を増やす可能性を検討しています。買戻しのタイミングと出来高は、自社株価、市場状況、および同社の資本状況などの要因を考慮して、経営陣の裁量によって決定されます。このプログラムは、権利証券の特定の数の取得をNovo Integrated Sciencesに約束するものではなく、いつでも中止することができます。この発表は、同社がSECに提出したForm 8-KのExhibit 99.1に添付されたプレスリリースで行われました。
役に立った
役に立たない